• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYBoard
  • MYInsights
  • Strategy & Consulting
  • Contact Us
Select Page
New Target for Multiple Myeloma

New Target for Multiple Myeloma

by MM360 Staff | Mar 23, 2021 | Featured News, Myeloma News, Uncategorized

A lot of progress has been made in myeloma, but there remains unmet need of patients who’ve exhausted many treatment options. In a new prospective, prospective, multicenter, single-arm clinical trial study published in Nature Medicine, the researchers used...
Optimizing the Use of MRD Testing in Multiple Myeloma

Optimizing the Use of MRD Testing in Multiple Myeloma

by MM360 Staff | Mar 20, 2021 | Featured News, Myeloma News

  Achieving minimal residual disease (MRD) negativity is an independent prognostic factor for survival in multiple myeloma (MM); however there remain questions about the optimal use of MRD. In a review published in Pathology, the journal of the Royal College of...
Switching Select Older Patients to Low Dose of Lenalidomide and Discontinuing Dex is Safe and Effective

Switching Select Older Patients to Low Dose of Lenalidomide and Discontinuing Dex is Safe and Effective

by MM360 Staff | Mar 19, 2021 | Featured News, Myeloma News

A new study published in Blood found that switching select older patients to a lower dose of lenalidomide and discontinuing dexamethasone after nine months was not only safe, but it also yielded similar outcomes as compared with patients who received continuous Rd....
Daratumumab Monotherapy Demonstrates Efficacy in R/R Myeloma

Daratumumab Monotherapy Demonstrates Efficacy in R/R Myeloma

by MM360 Staff | Feb 3, 2021 | Featured News, Myeloma News

A recent article published Feb. 2, 2021 in the Annals of Hematology demonstrated efficacy and safety of daratumumab (DARA) monotherapy in real-world patients. The GIMEMA Lazio group reported experience in 62 patients with relapsed/ refractory myeloma who had...
Only 26% of MM RCTs Report Racial Composition of Enrolled Patients

Only 26% of MM RCTs Report Racial Composition of Enrolled Patients

by MM360 Staff | Jan 20, 2021 | Featured News, Myeloma News

Despite improvement in overall survival for patients with multiple myeloma, racial minorities benefit less from these survival gains. Earlier research shows racial minorities are under-represented in multiple myeloma clinical trials, with scarce reporting of their...
« Older Entries
Next Entries »

Recent Content

  • Darzalex Regimen May Improve MRD Responses in Multiple Myeloma
  • Elranatamab monotherapy in the real-word setting in relapsed-refractory multiple myeloma: results of the French compassionate use program on behalf of the IFM
  • Hexamethylene amiloride induces lysosome-mediated cell death in multiple myeloma through transcription factor E3
  • Global disparities in drug-related adverse events of patients with multiple myeloma: a pharmacovigilance study
  • Black Patients With Myeloma Face Taste, Skin Side Effects from Talvey
  • ASH 2024: Expert Discusses Challenges, Future Research Opportunities With Bispecific Antibodies in Multiple Myeloma
  • Blenrep Combo Improves Survival in Relapsed/Refractory Multiple Myeloma
  • Pseudokinase TRIB3 stabilizes SSRP1 via USP10-mediated deubiquitination to promote multiple myeloma progression
  • Phase 3 GMMG-HD7 Trial: Assessing the Impact of Isatuximab on MRD Negativity and PFS in Multiple Myeloma
  • Phase 3 CEPHEUS Trial: DARA Plus VRd Is a Standard of Care for Frontline Treatment in Transplant-Ineligible Multiple Myeloma
  • Facebook
  • X
  • Instagram
©2016-2024 MYELOMA360
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT